75. クッシング病 Cushing disease Clinical trials / Disease details


臨床試験数 : 203 薬物数 : 196 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

  
11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01925092
(ClinicalTrials.gov)
August 20138/8/2013Mifepristone in Children With Refractory Cushing's DiseaseAn Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's DiseaseCushing's DiseaseDrug: mifepristoneCorcept TherapeuticsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Withdrawn6 Years17 YearsBoth0Phase 3United States
2NCT01371565
(ClinicalTrials.gov)
November 20107/6/2011Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's Disease;Cushing's SyndromeDrug: MifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll4Phase 3United States
3NCT00936741
(ClinicalTrials.gov)
July 20099/7/2009An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeAn Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's SyndromeDrug: mifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll30Phase 3United States
4EUCTR2007-007604-15-GB
(EUCTR)
03/03/200921/08/2008A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome - Glucocorticoid Receptor Antagonism in Sub-Clinical CushingsA Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome - Glucocorticoid Receptor Antagonism in Sub-Clinical Cushings Sub Clinical Cushing's Syndrome
MedDRA version: 9.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome
Trade Name: mifedren
Product Name: HRA052015 (mifepristone)
Product Code: HRA052015
INN or Proposed INN: MIFEPRISTONE
Sheffield Teaching Hospitals NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
6 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
5NCT00721201
(ClinicalTrials.gov)
November 200821/7/2008Glucocorticoid Receptor Antagonism in Subclinical CushingsA Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical CushingsSubclinical Cushing'sDrug: MifepristoneSheffield Teaching Hospitals NHS Foundation TrustHRA PharmaCompleted18 YearsN/AAll6Phase 1/Phase 2United Kingdom
6NCT00569582
(ClinicalTrials.gov)
December 20075/12/2007A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeAn Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's SyndromeDrug: mifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll50Phase 3United States
7NCT00422201
(ClinicalTrials.gov)
May 15, 200712/1/2007Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionProspective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionCushing's SyndromeDrug: MifepristoneHRA PharmaNULLTerminated18 Years85 YearsAll18Phase 2United States;France;Germany;Italy;Netherlands;United Kingdom
8EUCTR2006-004679-36-DE
(EUCTR)
05/04/200709/10/2006Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 14.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Classification code 10014146;Term: Ectopic ACTH syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
35France;United States;Netherlands;Germany;Italy
9EUCTR2006-004679-36-NL
(EUCTR)
22/03/200731/01/2007Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome
Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
22Germany;Netherlands;France;Italy
10EUCTR2006-004679-36-IT
(EUCTR)
15/01/200730/01/2007Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS Cushing s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone ACTH Secretion
MedDRA version: 9.1;Level: LLT;Classification code 10014146;Term: Ectopic ACTH syndrome
Product Name: Mifepristone
Product Code: HRA052015
LABORATOIRE HRA PHARMANULLNot RecruitingFemale: yes
Male: yes
22Germany;Netherlands;France;Italy
11EUCTR2006-004679-36-FR
(EUCTR)
13/12/200629/09/2006Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome
Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
22France;Netherlands;Germany;Italy